Benitec Biopharma (BNTC) Proxy Filing summary

Executive summary

• Special Meeting scheduled for August 29, 2024, to be held virtually, allowing shareholders to vote and submit questions online.

• Three main proposals: approval of potential issuance of shares upon warrant exercise (Nasdaq compliance), amendment to the 2020 Equity and Incentive Compensation Plan, and possible adjournment to solicit more votes.

• Record date for voting eligibility is July 25, 2024, with 10,086,119 shares outstanding.

Voting matters and shareholder proposals

• Proposal 1: Approve potential issuance of shares upon exercise of certain warrants, which could trigger a change of control under Nasdaq rules.

• Proposal 2: Approve amendment to increase shares authorized under the 2020 Equity and Incentive Compensation Plan by 7,000,000 shares, raising the total to 8,204,537.

• Proposal 3: Approve adjournment or postponement of the meeting if more time is needed to solicit votes for Proposals 1 or 2.

• All proposals require a majority of shares present or represented by proxy to pass; abstentions count as votes against, broker non-votes have no effect.

Board of directors and corporate governance

• Board recommends voting FOR all three proposals.

• Recent appointment of Kishen Mehta to the Board as part of a private placement agreement.

• Board and Compensation Committee oversee the administration of the equity plan and compensation matters.